Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
AustraliaIPO:
06 January 1999Website:
http://www.kaziatherapeutics.comNext earnings report:
04 October 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 17 min agoDividend
Analysts recommendations
Institutional Ownership
KZIA Latest News
SYDNEY , Sept. 12, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination).
Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers?
Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.
Kazia Therapeutics (NASDAQ: KZIA ) stock is continuing to rally on Thursday after the company reported positive alongside clinical trial data yesterday. The Kazia Therapeutics clinical trial covered the company's paxalisib as a treatment of glioblastoma.
Kazia Therapeutics (NASDAQ: KZIA ) stock is soaring higher on Wednesday after the oncology-focused biotechnology company provided results from a Phase II/III clinical trial. These results concern the effectiveness of paxalisib as a treatment of glioblastoma versus the standard of care (SOC).
GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma SYDNEY , July 10, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma (NCT03522298), a life-threatening brain cancer, where there is an urgent unmet need for new therapeutics. GBM AGILE STUDY GBM AGILE is an adaptive phase II/III global trial sponsored by the Global Coalition for Adaptive Research (GCAR), a nonprofit organization comprised of some of the world's foremost clinical, translational, and basic science researchers, from institutions such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.
SYDNEY , June 27, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data from its lead program, paxalisib, at the upcoming 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) June 29 – July 2, 2024, in Philadelphia, PA. Kazia concurrently announces publication of an article in European Journal of Cancer highlighting the need for evaluating mutation-specific, CNS penetrant, inhibitors to treat pediatric patients with Diffuse Midline Glioma (DMG).
What type of business is Kazia Therapeutics Limited?
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
What sector is Kazia Therapeutics Limited in?
Kazia Therapeutics Limited is in the Healthcare sector
What industry is Kazia Therapeutics Limited in?
Kazia Therapeutics Limited is in the Biotechnology industry
What country is Kazia Therapeutics Limited from?
Kazia Therapeutics Limited is headquartered in Australia
When did Kazia Therapeutics Limited go public?
Kazia Therapeutics Limited initial public offering (IPO) was on 06 January 1999
What is Kazia Therapeutics Limited website?
https://www.kaziatherapeutics.com
Is Kazia Therapeutics Limited in the S&P 500?
No, Kazia Therapeutics Limited is not included in the S&P 500 index
Is Kazia Therapeutics Limited in the NASDAQ 100?
No, Kazia Therapeutics Limited is not included in the NASDAQ 100 index
Is Kazia Therapeutics Limited in the Dow Jones?
No, Kazia Therapeutics Limited is not included in the Dow Jones index
When was Kazia Therapeutics Limited the previous earnings report?
No data
When does Kazia Therapeutics Limited earnings report?
The next expected earnings date for Kazia Therapeutics Limited is 04 October 2024